Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 764 | 175 | 578 |
| Samples | 266 | 74 | 187 |
| Peptides | 222 | 48 | 176 |
Function
FMO5 · Flavin containing dimethylaniline monoxygenase 5
Metabolic N-oxidation of the diet-derived amino-trimethylamine (TMA) is mediated by flavin-containing monooxygenase and is subject to an inherited FMO3 polymorphism in man resulting in a small subpopulation with reduced TMA N-oxidation capacity resulting in fish odor syndrome Trimethylaminuria. Three forms of the enzyme, FMO1 found in fetal liver, FMO2 found in adult liver, and FMO3 are encoded by genes clustered in the 1q23-q25 region. Flavin-containing monooxygenases are NADPH-dependent flavoenzymes that catalyzes the oxidation of soft nucleophilic heteroatom centers in drugs, pesticides, and xenobiotics. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2009].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 208 amino-acid changes on canonical ENST00000254090 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FMO5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FMO5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 18/612 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Germ Cell Tumour | 0/25 0% | 3/169 2% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Osteosarcoma | 3/45 7% | 0/166 0% |
| Mesothelioma | 3/62 5% | 0/165 0% |
| Melanoma | 3/210 1% | 24/1899 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 8/810 1% |
| Plasma Cell Myeloma | 4/44 9% | 0/305 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Colorectal Carcinoma | 6/143 4% | 29/3239 1% |
| Bladder Carcinoma | 3/58 5% | 7/956 1% |
| Gastric Carcinoma | 2/74 3% | 13/1809 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 8/1390 1% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Other Solid Cancers | 1/94 1% | 7/1515 0% |
| Breast Carcinoma | 7/144 5% | 8/3264 0% |
| Non-Cancerous | 1/104 1% | 3/830 0% |
| Esophageal Squamous Cell Carcinoma | 6/51 12% | 5/2550 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Kidney Carcinoma | 0/85 0% | 5/1862 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
Mutation Distribution
Where FMO5 is mutated · all tissues, split by cell line vs tissue
How many mutations in FMO5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 764 mutations in FMO5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|